ACBD5

Across TCGA pan-cancer cohorts, ACBD5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACBD5 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACBD5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACBD5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where ACBD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.467	0.823	.001	35	view →
UCEC	OS	Median	III,IV	1.000	0.311	.001	28	view →
PDAC	DFS	Median	III,IV	0.514	0.196	.011	7	view →
GBM	DFS	Tertile	All	0.575	0.820	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACBD5–LUAD (DFS)

Open the LUAD breakdown →